- call +1-201-465-4211
- email sales@mrinsights.biz
Cystic fibrosis is a genetic disease that causes continuous lung infections and breathing problem over time. It is a progressive disease. The presence of imperfect gene causes a thick, sticky buildup of mucus in the lungs, intestine liver, pancreas, and other organs. The mucus in the lungs clogs airways and traps bacteria leading to infections that causes savior lung damage, and respiratory failure. The mucus prevents in the pancreas discharge the digestive enzymes that allow the body to break down food and absorb vital nutrients. This disease is caused by mutation in gene, cystic fibrosis trans membrane conductance regulator (CFTR) is a membrane protein in vertebrates, a protein required for regulating sweat, mucus and body secretions.
Scope of the Report:
This report focuses on the Cystic Fibrosis (CF) Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Cystic Fibrosis (CF) Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Vertex Pharmaceuticals Incorporated
Gilead
AbbVie, Inc.
Novartis AG
F. Hoffmann-La Roche Ltd
Alaxia
Merck & Co. Inc.
AIT (Advanced Inhalation Therapies)
ALLERGAN
AstraZeneca
Teva Pharmaceutical Industries Ltd
Alcresta
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Pancreatic enzyme supplements
Mucolytics
Bronchodilators
CFTR modulators
Market Segment by Applications, can be divided into
Oral drugs
Inhaled drugs
There are 15 Chapters to deeply display the global Cystic Fibrosis (CF) Therapeutics market.
Chapter 1, to describe Cystic Fibrosis (CF) Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Cystic Fibrosis (CF) Therapeutics, with sales, revenue, and price of Cystic Fibrosis (CF) Therapeutics, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Cystic Fibrosis (CF) Therapeutics, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Cystic Fibrosis (CF) Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Cystic Fibrosis (CF) Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Cystic Fibrosis (CF) Therapeutics Introduction
1.2 Market Analysis by Type
1.2.1 Pancreatic enzyme supplements
1.2.2 Mucolytics
1.2.3 Bronchodilators
1.2.4 CFTR modulators
1.3 Market Analysis by Applications
1.3.1 Oral drugs
1.3.2 Inhaled drugs
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Vertex Pharmaceuticals Incorporated
2.1.1 Business Overview
2.1.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Vertex Pharmaceuticals Incorporated Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Gilead
2.2.1 Business Overview
2.2.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Gilead Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 AbbVie, Inc.
2.3.1 Business Overview
2.3.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 AbbVie, Inc. Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novartis AG
2.4.1 Business Overview
2.4.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Novartis AG Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 F. Hoffmann-La Roche Ltd
2.5.1 Business Overview
2.5.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Alaxia
2.6.1 Business Overview
2.6.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Alaxia Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Merck & Co. Inc.
2.7.1 Business Overview
2.7.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Merck & Co. Inc. Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 AIT (Advanced Inhalation Therapies)
2.8.1 Business Overview
2.8.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 ALLERGAN
2.9.1 Business Overview
2.9.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 ALLERGAN Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 AstraZeneca
2.10.1 Business Overview
2.10.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 AstraZeneca Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Teva Pharmaceutical Industries Ltd
2.11.1 Business Overview
2.11.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Alcresta
2.12.1 Business Overview
2.12.2 Cystic Fibrosis (CF) Therapeutics Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Alcresta Cystic Fibrosis (CF) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Cystic Fibrosis (CF) Therapeutics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Cystic Fibrosis (CF) Therapeutics Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Cystic Fibrosis (CF) Therapeutics Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Cystic Fibrosis (CF) Therapeutics Manufacturer Market Share in 2017
3.3.2 Top 6 Cystic Fibrosis (CF) Therapeutics Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Cystic Fibrosis (CF) Therapeutics Market Analysis by Regions
4.1 Global Cystic Fibrosis (CF) Therapeutics Sales, Revenue and Market Share by Regions
4.1.1 Global Cystic Fibrosis (CF) Therapeutics Sales and Market Share by Regions (2013-2018)
4.1.2 Global Cystic Fibrosis (CF) Therapeutics Revenue and Market Share by Regions (2013-2018)
4.2 North America Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
4.3 Europe Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
4.5 South America Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
5 North America Cystic Fibrosis (CF) Therapeutics by Countries
5.1 North America Cystic Fibrosis (CF) Therapeutics Sales, Revenue and Market Share by Countries
5.1.1 North America Cystic Fibrosis (CF) Therapeutics Sales and Market Share by Countries (2013-2018)
5.1.2 North America Cystic Fibrosis (CF) Therapeutics Revenue and Market Share by Countries (2013-2018)
5.2 United States Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
5.3 Canada Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
5.4 Mexico Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
6 Europe Cystic Fibrosis (CF) Therapeutics by Countries
6.1 Europe Cystic Fibrosis (CF) Therapeutics Sales, Revenue and Market Share by Countries
6.1.1 Europe Cystic Fibrosis (CF) Therapeutics Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Cystic Fibrosis (CF) Therapeutics Revenue and Market Share by Countries (2013-2018)
6.2 Germany Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
6.3 UK Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
6.4 France Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
6.5 Russia Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
6.6 Italy Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
7 Asia-Pacific Cystic Fibrosis (CF) Therapeutics by Countries
7.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue and Market Share by Countries (2013-2018)
7.2 China Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
7.3 Japan Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
7.4 Korea Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
7.5 India Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
8 South America Cystic Fibrosis (CF) Therapeutics by Countries
8.1 South America Cystic Fibrosis (CF) Therapeutics Sales, Revenue and Market Share by Countries
8.1.1 South America Cystic Fibrosis (CF) Therapeutics Sales and Market Share by Countries (2013-2018)
8.1.2 South America Cystic Fibrosis (CF) Therapeutics Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
8.3 Argentina Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
8.4 Colombia Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
9 Middle East and Africa Cystic Fibrosis (CF) Therapeutics by Countries
9.1 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
9.3 UAE Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
9.4 Egypt Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
9.5 Nigeria Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
9.6 South Africa Cystic Fibrosis (CF) Therapeutics Sales and Growth Rate (2013-2018)
10 Global Cystic Fibrosis (CF) Therapeutics Market Segment by Type
10.1 Global Cystic Fibrosis (CF) Therapeutics Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Cystic Fibrosis (CF) Therapeutics Sales and Market Share by Type (2013-2018)
10.1.2 Global Cystic Fibrosis (CF) Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Pancreatic enzyme supplements Sales Growth and Price
10.2.1 Global Pancreatic enzyme supplements Sales Growth (2013-2018)
10.2.2 Global Pancreatic enzyme supplements Price (2013-2018)
10.3 Mucolytics Sales Growth and Price
10.3.1 Global Mucolytics Sales Growth (2013-2018)
10.3.2 Global Mucolytics Price (2013-2018)
10.4 Bronchodilators Sales Growth and Price
10.4.1 Global Bronchodilators Sales Growth (2013-2018)
10.4.2 Global Bronchodilators Price (2013-2018)
10.5 CFTR modulators Sales Growth and Price
10.5.1 Global CFTR modulators Sales Growth (2013-2018)
10.5.2 Global CFTR modulators Price (2013-2018)
11 Global Cystic Fibrosis (CF) Therapeutics Market Segment by Application
11.1 Global Cystic Fibrosis (CF) Therapeutics Sales Market Share by Application (2013-2018)
11.2 Oral drugs Sales Growth (2013-2018)
11.3 Inhaled drugs Sales Growth (2013-2018)
12 Cystic Fibrosis (CF) Therapeutics Market Forecast (2018-2023)
12.1 Global Cystic Fibrosis (CF) Therapeutics Sales, Revenue and Growth Rate (2018-2023)
12.2 Cystic Fibrosis (CF) Therapeutics Market Forecast by Regions (2018-2023)
12.2.1 North America Cystic Fibrosis (CF) Therapeutics Market Forecast (2018-2023)
12.2.2 Europe Cystic Fibrosis (CF) Therapeutics Market Forecast (2018-2023)
12.2.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Forecast (2018-2023)
12.2.4 South America Cystic Fibrosis (CF) Therapeutics Market Forecast (2018-2023)
12.2.5 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Market Forecast (2018-2023)
12.3 Cystic Fibrosis (CF) Therapeutics Market Forecast by Type (2018-2023)
12.3.1 Global Cystic Fibrosis (CF) Therapeutics Sales Forecast by Type (2018-2023)
12.3.2 Global Cystic Fibrosis (CF) Therapeutics Market Share Forecast by Type (2018-2023)
12.4 Cystic Fibrosis (CF) Therapeutics Market Forecast by Application (2018-2023)
12.4.1 Global Cystic Fibrosis (CF) Therapeutics Sales Forecast by Application (2018-2023)
12.4.2 Global Cystic Fibrosis (CF) Therapeutics Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Cystic Fibrosis (CF) Therapeutics Picture
Table Product Specifications of Cystic Fibrosis (CF) Therapeutics
Figure Global Sales Market Share of Cystic Fibrosis (CF)
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
